Sepracor, Inc., a research-based pharmaceutical company, engages in the discovery, development, and commercialization of differentiated products primarily for the treatment of respiratory and central nervous system disorders. It commercializes two proprietary products, LUNESTA eszopiclone for the treatment of insomnia in patients who experience difficulty falling asleep, as well as for the treatment of patients who have difficulty sleeping through the night; and XOPENEX levalbuterol Inhalation Solution, a short-acting bronchodilator, for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease, such as asthma. Additionally, XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler is approved for the treatment or prevention of bronchospasm in adults, adolescents, and children four years of age and older with reversible obstructive airway disease. The company also has two drug candidates in Phase II and other drug compounds in earlier stages of development, including (S)-amlodipine for the treatment of hypertension; SEP-226330 for the treatment of restless legs syndrome; SEP-225289 for the treatment of depression; and SEP-227162 also for the treatment of depression. In addition, Sepracor has out-licensed the rights to various marketed drugs that include Schering-Plough's CLARINEX (desloratadine); sanofi-aventis's ALLEGRA (fexofenadine HCl); UCB Pharma's XYZAL/XUSAL (levocetirizine). Additionally, Sepracor has a research and development collaboration with ACADIA Pharmaceuticals to investigate potential clinical candidates targeted toward the treatment of central nervous system disorders. Sepracor was founded by Timothy J. Barberich in 1984 and is headquartered in Marlborough, Massachusetts.
Premarket, intraday, nightly, and weekend updates, which include stock picks with full instructions, market direction (short, intermediate, long term), precious metal, commodity, and currency analysis.
Provide you stock picks (breakouts) and market direction to help you become
more profitable.
Voice over chart updates sent to you by e-mail. These updates contain stock picks and market status for a number of different portfolios, which Trending123 is recommending and following.
Instantaneous e-mail alerts during the trading day when targets have been hit or the status of a position or the market warrants a move. Stock Recommendations for swing traders, day traders, and long term investors.
Receive instant emails to your computer, organizer, cell phone of breakouts on stocks.....Learn More
Stock quotes, stock research, stock scan and picks and free stock chart pattern recognition from Trending 123.com for smart stock market investing. We feature daily stock market email alerts including equities, indices, and currencies, identified through technical analysis trends patterns and waves. Sign up today!
Financial Market Data powered by Quotemedia.com. All rights reserved. Terms and conditions.
NYSE/AMEX data delayed 20 minutes. NASDAQ/other data delayed 15 minutes unless indicated.
